Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 16
2024
|
J Scott Kirby Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,912
+34.08%
|
$165,984
$57.52 P/Share
|
May 16
2024
|
Michael F Mahoney Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,184
+35.31%
|
$124,488
$57.52 P/Share
|
May 16
2024
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+50.0%
|
$131,898
$57.52 P/Share
|
May 16
2024
|
C David Brown Ii Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+1.87%
|
$131,898
$57.52 P/Share
|
May 16
2024
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+6.78%
|
$131,898
$57.52 P/Share
|
May 16
2024
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,347
+6.37%
|
$133,779
$57.52 P/Share
|
May 16
2024
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,184
+23.08%
|
$124,488
$57.52 P/Share
|
May 02
2024
|
Michael F Mahoney Director |
BUY
Open market or private purchase
|
Direct |
9,181
+49.53%
|
$495,774
$54.49 P/Share
|
May 02
2024
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
1,000
+4.42%
|
$53,000
$53.88 P/Share
|
Apr 01
2024
|
J. David Joyner EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
28,280
+39.0%
|
-
|
Apr 01
2024
|
Laurie P. Havanec EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,426
+50.0%
|
$744,654
$79.56 P/Share
|
Apr 01
2024
|
Laurie P. Havanec EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,630
-16.89%
|
$602,770
$79.56 P/Share
|
Apr 01
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,913
+22.61%
|
$546,127
$79.56 P/Share
|
Apr 01
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,298
-8.88%
|
$181,542
$79.56 P/Share
|
Apr 01
2024
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,683
+41.42%
|
$843,957
$79.56 P/Share
|
Apr 01
2024
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,004
-14.03%
|
$237,316
$79.56 P/Share
|
Apr 01
2024
|
Samrat S. Khichi EVP, CPO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,569
+22.03%
|
-
|
Apr 01
2024
|
Brian A Kane EVP/President, Aetna |
BUY
Grant, award, or other acquisition
|
Direct |
12,569
+50.0%
|
-
|
Apr 01
2024
|
Tilak Mandadi EVP, Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,339
+16.46%
|
-
|
Apr 01
2024
|
Prem S Shah EVP and Pres-Pharm, Consumer W |
BUY
Grant, award, or other acquisition
|
Direct |
15,082
+28.93%
|
-
|
Apr 01
2024
|
Prem S Shah EVP and Pres-Pharm, Consumer W |
SELL
Payment of exercise price or tax liability
|
Direct |
7,892
-8.2%
|
$623,468
$79.56 P/Share
|
Apr 01
2024
|
Thomas F. Cowhey EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,082
+23.91%
|
-
|
Apr 01
2024
|
Thomas F. Cowhey EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,719
-4.6%
|
$135,801
$79.56 P/Share
|
Apr 01
2024
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
61,953
-45.34%
|
$4,894,287
$79.56 P/Share
|
Apr 01
2024
|
Karen S Lynch President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
45,248
+50.0%
|
$3,574,592
$79.56 P/Share
|
Feb 28
2024
|
Thomas F. Cowhey EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,641
-16.46%
|
$423,075
$75.19 P/Share
|
Feb 28
2024
|
J. David Joyner EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
1,970
-4.62%
|
$147,750
$75.19 P/Share
|
Feb 28
2024
|
Samrat S. Khichi EVP, CPO and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,210
-38.91%
|
$465,750
$75.19 P/Share
|
Feb 26
2024
|
Prem S Shah EVP and Pres-Pharm, Consumer W |
SELL
Payment of exercise price or tax liability
|
Direct |
261
-0.6%
|
$19,836
$76.43 P/Share
|
Feb 26
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
355
-3.66%
|
$26,980
$76.43 P/Share
|
Feb 26
2024
|
Laurie P. Havanec EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,698
-12.91%
|
$509,048
$76.43 P/Share
|
Feb 16
2024
|
Prem S Shah EVP and Pres-Pharm, Consumer W |
SELL
Open market or private sale
|
Direct |
29,473
-42.57%
|
$2,239,948
$76.95 P/Share
|
Feb 12
2024
|
Laurie P. Havanec EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,817
+31.13%
|
-
|
Feb 12
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,926
+18.22%
|
-
|
Feb 12
2024
|
Prem S Shah EVP and Pres-Pharm, Consumer W |
BUY
Grant, award, or other acquisition
|
Direct |
13,313
+16.13%
|
-
|
Feb 12
2024
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,452
+25.54%
|
-
|
Feb 12
2024
|
Karen S Lynch President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
136,640
+50.0%
|
-
|
Dec 14
2023
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-1.37%
|
$8,296
$68.48 P/Share
|
Dec 07
2023
|
Anne A. Finucane Director |
SELL
Bona fide gift
|
Direct |
3,450
-32.3%
|
$255,300
$74.28 P/Share
|
Nov 30
2023
|
Thomas F. Cowhey EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,358
+10.77%
|
$492,986
$67.95 P/Share
|
Nov 15
2023
|
J Scott Kirby Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,422
+47.09%
|
$167,118
$69.13 P/Share
|
Nov 15
2023
|
Michael F Mahoney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,817
+50.0%
|
$125,373
$69.13 P/Share
|
Nov 15
2023
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,925
+36.41%
|
$132,825
$69.13 P/Share
|
Nov 15
2023
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,925
+6.12%
|
$132,825
$69.13 P/Share
|
Nov 15
2023
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,925
+15.27%
|
$132,825
$69.13 P/Share
|
Nov 15
2023
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,998
+5.85%
|
$137,862
$69.13 P/Share
|
Nov 15
2023
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,817
+26.3%
|
$125,373
$69.13 P/Share
|
Nov 03
2023
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
2,000
+8.84%
|
$140,000
$70.47 P/Share
|
Oct 02
2023
|
J Scott Kirby Director |
BUY
Grant, award, or other acquisition
|
Direct |
299
+50.0%
|
$20,631
$69.82 P/Share
|
Aug 31
2023
|
Tilak Mandadi EVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,053
-39.22%
|
$848,445
$65.17 P/Share
|